Moderna nearly tripled in a day on a successful cancer-vaccine trial, then slid back overnight from 194.95 to about 158. This call is about that giveback.
Three things overlap at 163-167: the high made on the heaviest volume yet closing far below it, the weak bounce on 85% less volume, and the halfway mark of the surge.
A move back above 171 would end the run of lower highs and prove this wrong, which is why the stop sits just above it at 172.5.
The full analysis is for members
Analysis by methodology (ICT, Wyckoff, Elliott, divergence, macro, news), invalidation levels, R:R and confidence are in the member report.
